ZEB1 and breast carcinoma: Kikuchi et al demonstrated that Phenylbutyrate, a histone deacetylase antagonist that also exhibits antitumor activity sensitivity, was reported to be influenced by epigenetic expression alteration of ZEB1 in breast cancer cells [15].